Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tango Therapeutics, Inc. - Common Stock
(NQ:
TNGX
)
1.840
-0.030 (-1.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tango Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Which stocks are experiencing notable movement on Monday?
May 19, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
May 19, 2025
Via
Benzinga
Earnings Scheduled For May 12, 2025
May 12, 2025
Via
Benzinga
Insights into Tango Therapeutics's Upcoming Earnings
May 09, 2025
Via
Benzinga
Unveiling 5 Analyst Insights On Tango Therapeutics
December 05, 2024
Via
Benzinga
The Analyst Landscape: 5 Takes On Tango Therapeutics
November 11, 2024
Via
Benzinga
Analyst Scoreboard: 4 Ratings For Tango Therapeutics
September 10, 2024
Via
Benzinga
Analyst Expectations For Tango Therapeutics's Future
August 08, 2024
Via
Benzinga
Expert Outlook: Tango Therapeutics Through The Eyes Of 6 Analysts
July 09, 2024
Via
Benzinga
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 06, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 06, 2024
Via
Benzinga
Forecasting The Future: 4 Analyst Projections For Tango Therapeutics
May 24, 2024
Via
Benzinga
Recap: Tango Therapeutics Q4 Earnings
March 18, 2024
Via
Benzinga
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
November 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 10, 2024
Via
Benzinga
Tango Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 07, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
May 23, 2024
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 23, 2024
Via
Benzinga
Tango Therapeutics Announces Discontinuation of TNG348 Program
May 23, 2024
From
Tango Therapeutics
Via
Business Wire
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 08, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 18, 2024
TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
March 18, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.